Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1984 Jul;52(1):49–52. doi: 10.1136/hrt.52.1.49

Acute haemodynamic effects of oral prenalterol in severe heart failure.

M C Petch, C Wisbey, O Ormerod, C Scott, R M Goodfellow
PMCID: PMC481583  PMID: 6146324

Abstract

The acute haemodynamic effects of oral prenalterol were studied in 14 patients with severe heart failure (NYHA class III) due to ischaemic heart disease. All had received treatment with digoxin, diuretics, and in most cases vasodilators. Prenalterol was administered at two hourly intervals to give cumulative doses of 20, 50, and 100 mg and mean plasma concentrations of 53, 97, and 175 nmol/l. Haemodynamic measurements were made two hours after each dose with Swan-Ganz catheterisation; cardiac output was measured by thermodilution. There were no significant changes in heart rate, mean arterial pressure, or pulmonary artery diastolic pressure after the drug. Cardiac index rose significantly after 50 mg and 100 mg prenalterol. Oral prenalterol has a beneficial short term haemodynamic effect in patients with severe heart failure. If this effect is sustained prenalterol may be of value in the long term management of patients with this disabling condition.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold S. B., Byrd R. C., Meister W., Melmon K., Cheitlin M. D., Bristow J. D., Parmley W. W., Chatterjee K. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980 Dec 18;303(25):1443–1448. doi: 10.1056/NEJM198012183032503. [DOI] [PubMed] [Google Scholar]
  2. Awan N. A., Needham K. E., Evenson M. K., Win A., Mason D. T. Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease. Am Heart J. 1981 Feb;101(2):158–161. doi: 10.1016/0002-8703(81)90659-1. [DOI] [PubMed] [Google Scholar]
  3. Carlsson E., Dahlöf C. G., Hedberg A., Persson H., Tångstrand B. Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 1977 Nov;300(2):101–105. doi: 10.1007/BF00505039. [DOI] [PubMed] [Google Scholar]
  4. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  5. Erbel R., Meyer J., Lambertz H., Schweizer P., Voelker W., Krebs W., Braun G., Effert S. Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy. Circulation. 1982 Aug;66(2):361–369. doi: 10.1161/01.cir.66.2.361. [DOI] [PubMed] [Google Scholar]
  6. Griffiths B. E., Penny W. J., Lewis M. J., Henderson A. H. Maintenance of the inotropic effect of digoxin on long-term treatment. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1819–1822. doi: 10.1136/bmj.284.6332.1819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kendall M. J., Goodfellow R. M., Westerling S. Prenalterol--a new cardioselective inotropic agent. J Clin Hosp Pharm. 1982 Jun;7(2):107–118. doi: 10.1111/j.1365-2710.1982.tb01010.x. [DOI] [PubMed] [Google Scholar]
  8. Kirlin P. C., Pitt B. Hemodynamic effects of intravenous prenalterol in severe heart failure. Am J Cardiol. 1981 Mar;47(3):670–675. doi: 10.1016/0002-9149(81)90553-1. [DOI] [PubMed] [Google Scholar]
  9. Kupper W., Schütt M., Bleifeld W. Effect of intravenous prenalterol on haemodynamics and myocardial lactate extraction in patients with left ventricular failure. Acta Med Scand Suppl. 1982;659:287–298. doi: 10.1111/j.0954-6820.1982.tb00853.x. [DOI] [PubMed] [Google Scholar]
  10. Lee D. C., Johnson R. A., Bingham J. B., Leahy M., Dinsmore R. E., Goroll A. H., Newell J. B., Strauss H. W., Haber E. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982 Mar 25;306(12):699–705. doi: 10.1056/NEJM198203253061202. [DOI] [PubMed] [Google Scholar]
  11. Manders W. T., Vatner S. F., Braunwald E. Cardio-selective beta adrenergic stimulation with prenalterol in the conscious dog. J Pharmacol Exp Ther. 1980 Oct;215(1):266–270. [PubMed] [Google Scholar]
  12. Mattsson H., Hedberg A., Carlsson E. Basic pharmacological properties of prenalterol. Acta Med Scand Suppl. 1982;659:9–37. doi: 10.1111/j.0954-6820.1982.tb00833.x. [DOI] [PubMed] [Google Scholar]
  13. Murray R. G., Tweddel A. C., Martin W., Pearson D., Hutton I., Lawrie T. D. Evaluation of digitalis in cardiac failure. Br Med J (Clin Res Ed) 1982 May 22;284(6328):1526–1528. doi: 10.1136/bmj.284.6328.1526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Petch M. C. Digoxin for heart failure in sinus rhythm. Thorax. 1979 Apr;34(2):147–149. doi: 10.1136/thx.34.2.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tweddel A. C., Murray R. G., Pearson D., Martin W., Hutton I. Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure. Br Heart J. 1982 Apr;47(4):375–380. doi: 10.1136/hrt.47.4.375. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES